ROIV
Roivant Sciences Ltd. · Healthcare
CEO Matthew Gline sold $74K of Roivant Sciences Ltd.
Sold$74,233
$3.71Price
20,009Shares
−2%Stake
What ROIV did after the filing
- The stock from Mon, Aug 29 open, $3.89
- +11.1%
- S&P 500, same days
- −10.7%
Measured over 30 trading days, to the Oct 11 close.
Traded Wed, Aug 24. Filed Fri, Aug 26, 7:00 PM ET, after the close. Returns use the Aug 29 open and the Oct 11 close. Not investment advice.